Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
EU research project for the development and validation of innovative, animal-free test methods (NAMs) for biomedical research and regulatory safety assessment. Applications until 16.04.2026 (Deadline: 16.04.2026).
Discover your potential with AI support
- Find out if this grant matches your project
- Develop your application together with AI
- Get matched with many more suitable grants
Grant criteria
Funding objective
Support for the paradigmatic shift in biomedical research and substance safety assessment through the full integration of human-relevant New Approach Methodologies (NAMs) across the entire spectrum from basic research to clinical application and regulatory evaluation.
Eligible expenses
- Research and development costs
- Personnel expenses
- Material costs
- Subcontractor costs
- Travel expenses
Non-eligible expenses
- Acquisition of real estate
- Debt repayment
Eligible to apply
- Companies
- Educational Institutions
- Non-profit Organizations
- Public Institutions
Funding requirements
- Legal residence in an EU member state or associated country
- Cooperation of multiple partners from research, industry, and regulatory authorities
- Participation in cluster activities and networking
- Conducting an open market consultation prior to submission
Documents required for application
- Project description
- Financial plan
- Curriculum vitae of the researchers
- Market analysis
- Tender documents
Evaluation criteria
- Innovative content of the project
- Scientific excellence
- Relevance to health research
- Methodological quality
- Expected regulatory impact
Description
The EU-funded research project “Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing” focuses on a comprehensive shift away from animal-based methods towards human-relevant, animal-free testing approaches. Within a budget framework of €5–8 million per project, innovative technologies such as in vitro assays, organoid models, organ-on-chip systems, iPSC applications, virtual twins, and AI-supported models are developed and validated. The entire spectrum of biomedical research is covered – from basic research through clinical translation to the regulatory safety assessment of pharmaceuticals, chemicals, and medical devices. Funding is provided to small and medium-sized enterprises, universities, research institutions, nonprofit and public organizations based in EU member states or associated countries. A prerequisite is the cooperation of multiple partners from research, industry, and regulatory authorities, participation in cluster networks, as well as an open market consultation prior to application submission. The funding amount covers 100% of R&D costs, personnel, consumables, subcontractors, and travel expenses (exception: real estate and debt refinancing). The submission deadline is 16/04/2026.
Evaluation is conducted by independent experts based on the degree of innovation, scientific excellence, relevance to health research, methodological quality, and expected regulatory impact. Funded consortia commit to joint networking and dissemination activities within a dedicated work package. The goal is to provide robust and scalable NAM platforms enabling industry and regulatory authorities to generate human-relevant data, facilitate regulatory approvals, and ultimately advance the transition away from animal testing.
Ready to secure your funding?
Register now and let our AI guide you through the application process – from eligibility check to finished application.